Open AccessComparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance)
Author(s) -
Lawrence N. Shulman,
Donald A. Berry,
Constance Cirrincione,
Heather P. Becker,
Edith A. Perez,
Ruth O’Regan,
Silvana Martino,
Charles L. Shapiro,
Charles Schneider,
Gretchen Kimmick,
Harold J. Burstein,
Larry Norton,
Hyman B. Muss,
Clifford A. Hudis,
Eric P. Winer
Publication year - 2014
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/pzay-5w26
Subject(s) - paclitaxel , cyclophosphamide , breast cancer , alliance , doxorubicin , oncology , adjuvant , medicine , adjuvant therapy , axillary lymph nodes , cancer , chemotherapy , political science , law